DCM
SCPH

DAFNA Capital Management’s scPharmaceuticals SCPH Stock Holding History

DAFNA Capital Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-38,891
Closed -$238K – 86
2021
Q2 		$238K Hold
38,891
– – 0.05% 83
2021
Q1 		$259K Hold
38,891
– – 0.06% 86
2020
Q4 		$206K Sell
38,891
-52,009
-57% -$407K 0.06% 73
2020
Q3 		$677K Sell
90,900
-9,100
-9% -$71.1K 0.22% 68
2020
Q2 		$736K Buy
+100,000
New +$878K 0.21% 68
2018
Q2 		– Sell
-55,844
Closed -$692K – 82
2018
Q1 		$692K Sell
55,844
-42,256
-43% -$568K 0.34% 55
2017
Q4 		$1.19M Buy
+98,100
New +$1.38M 0.64% 44

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

DAFNA Capital Management's SCPH Position: Q3 2021 in Review

DAFNA Capital Management sold out of scPharmaceuticals (SCPH) in Q3 2021, closing a stake of 38,891 shares — an estimated $238K sold.

DAFNA Capital Management first reported a position in SCPH in Q4 2017 and held it in 7 quarters. The position peaked at $1.19M in Q4 2017. 31 funds tracked by Wall St. Rank hold SCPH as of Q3 2021.

  • DAFNA Capital Management reported no remaining scPharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 38,891 scPharmaceuticals shares in Q3 2021, an estimated $238K.
  • DAFNA Capital Management first reported a position in scPharmaceuticals in Q4 2017 and held it in 7 quarters.
  • DAFNA Capital Management's scPharmaceuticals position peaked at $1.19M in Q4 2017.
  • 31 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2021.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.